MHRA paediatric investigation plan
Vyepti (EPTINEZUMAB)
MHRA paediatric investigation plan MHRA-100468-PIP01-22-M03 (update) · Modification
Key facts
| PIP number | MHRA-100468-PIP01-22-M03 (update) |
|---|---|
| Product names | Vyepti, VYEPTI 100 mg concent rate for solution for infusion, VYEPTI 300 mg concent rate for solution for infusion |
| Active substances | EPTINEZUMAB |
| Therapeutic areas | Neurology |
| Conditions | Prevention of migraine headaches |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Apr 8, 2025 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: